Purpose: Belatacept is a selective T-cell costimulation blocker indicated for prophylaxis of organ rejection in adult patients receiving a kidney transplant in combination with basiliximab induction, mycophenolate mofetil, and corticosteroids. It is the first maintenance immunosuppressive medication administered via intravenous infusion. To date, the majority of belatacept patients have received treatment through an institutional infusion facility. Home infusion may be preferred by some patients and providers; however, the safety profile of belatacept administered in the home infusion setting is not well described. This analysis described the preliminary safety experience in the home infusion setting. Methods: Nursing charts from home infusion visits were obtained from a service provider (BiologicTx). All patients who had received belatacept at home, from June 2011 to September 2014, were included. The primary outcome was the occurrence of any infusion-related safety event within 24 hours of a home infusion visit. Characteristics of belatacept-treated patients through the BiologicTx home infusion service at the time the first home infusion visit were described. Safety findings were summarized as the number of events divided by the total number of home infusion visits. Results: Forty-five patients received belatacept through the home infusion service during the study. The mean age of these patients at the time of the first visit was 58.7 years, and 64% were male. In total, there were 382 home infusion visits. The mean number of visits was 8.5 (with a median of 6 visits and a range from 1 to 29). Forty patients had more than one home infusion visit. Among patients with more than one home infusion visit, the mean duration between first recorded and most recent visit was 36 weeks (range, 2–128 weeks). Of 382 home infusion visits, there were no reports of infusion-related safety events within 24 hours after a visit. Conclusion: In this first preliminary analysis of kidney transplant recipients who received maintenance belatacept infusion in the home, there were no reports of home infusion–related safety events within 24 hours of a visit. This preliminary experience suggests that belatacept treatment through home infusion may be a reasonable alternative to institution-based infusions.

« Back to 2015 American Transplant Congress